Literature DB >> 2618733

Characteristics of the interaction of lycobetaine with DNA.

J Liu, S L Yang, B Xu.   

Abstract

The characteristics of the interaction of lycobetaine (LBT) with DNA were examined by fluorescence spectrometer, disc electrophoresis and restriction enzyme analysis. The apparent binding constant of LBT with calf thymus DNA has been determined as 1.67 x 10(6) L/mol by ethidium bromide displacement method. Based on electrophoresis titration, the mode of DNA binding was found to be through intercalation. Fluorescence quenching assay showed that the intrinsic association constant and the binding site size of LBT to calf thymus DNA were 0.26 x 10(6) L/mol and 2.6 base pairs, respectively. Selective inhibition of LBT on action of some restriction enzymes showed that LBT intercalate preferentially into GC base pairs. Neither DNA strand break nor interstrand cross-link was produced by LBT. LBT did not bind to DNA covalently and did not cause DNA alkylation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2618733

Source DB:  PubMed          Journal:  Zhongguo Yao Li Xue Bao        ISSN: 0253-9756


  4 in total

1.  Ungeremine effectively targets mammalian as well as bacterial type I and type II topoisomerases.

Authors:  Laura Casu; Filippo Cottiglia; Marco Leonti; Alessandro De Logu; Emanuela Agus; Yuk-Ching Tse-Dinh; Valentina Lombardo; Claudia Sissi
Journal:  Bioorg Med Chem Lett       Date:  2011-10-01       Impact factor: 2.823

2.  Lycobetaine acts as a selective topoisomerase II beta poison and inhibits the growth of human tumour cells.

Authors:  H U Barthelmes; E Niederberger; T Roth; K Schulte; W C Tang; F Boege; H H Fiebig; G Eisenbrand; D Marko
Journal:  Br J Cancer       Date:  2001-11-16       Impact factor: 7.640

3.  Development of antimetastatic drugs by targeting tumor sialic acids.

Authors:  Da-Yong Lu; Ting-Ren Lu; Hong-Ying Wu
Journal:  Sci Pharm       Date:  2012-06-18

4.  Inhibitions of several antineoplastic drugs on serum sialic Acid levels in mice bearing tumors.

Authors:  Da-Yong Lu; Jing Xu; Ting-Ren Lu; Hong-Ying Wu; Bin Xu
Journal:  Sci Pharm       Date:  2012-11-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.